Research ArticleRheumatoid Arthritis

Cystatin C as a Predictor of Renal Function and Methotrexate-Associated Toxicities in Patients With Rheumatoid Arthritis

Hyeok Chan Kwon, Mi Il Kang and So Mi Kim
The Journal of Rheumatology January 2024, 51 (1) 25-30; DOI: https://doi.org/10.3899/jrheum.2023-0218

REFERENCES

  1. 1.↵
    1. Karstila K,
    2. Korpela M,
    3. Sihvonen S,
    4. Mustonen J.
    Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. Clin Rheumatol 2007;26:2089-95.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Demoruelle MK,
    2. Deane KD.
    Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep 2012;14:472-80.
    OpenUrlPubMed
  3. 3.↵
    1. Karie S,
    2. Gandjbakhch F,
    3. Janus N, et al.
    Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the Matrix study. Rheumatology 2008;47:350-4.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Adu D,
    2. Berisa F,
    3. Howie AJ, et al.
    Glomerulonephritis in rheumatoid arthritis. Br J Rheumatol 1993;32:1008-11.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rheumatoid Arthritis Clinical Trial Archive Group
    . The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995;22:218-23.
    OpenUrlPubMed
  6. 6.↵
    1. Levey AS,
    2. Coresh J,
    3. Greene T, et al.
    Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Palacio-Lacambra ME,
    2. Comas-Reixach I,
    3. Blanco-Grau A,
    4. Suñé-Negre JM,
    5. Segarra-Medrano A,
    6. Montoro-Ronsano JB.
    Comparison of the Cockcroft–Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance. Br J Clin Pharmacol 2018;84:2120-8.
    OpenUrl
  8. 8.↵
    1. Levey AS,
    2. Stevens LA,
    3. Schmid CH, et al.
    A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Ix JH,
    2. Wassel CL,
    3. Stevens LA, et al.
    Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011;6:184-91.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Bökenkamp A,
    2. Herget-Rosenthal S,
    3. Bökenkamp R.
    Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006;21:1223-30.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Chew JS,
    2. Saleem M,
    3. Florkowski CM,
    4. George PM.
    Cystatin C—a paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008;29:47-62.
    OpenUrlPubMed
  12. 12.↵
    1. Yun HW,
    2. Kim CJ,
    3. Kim JW,
    4. Kim HA,
    5. Suh CH,
    6. Jung JY.
    The assessment of muscle mass and function in patients with longstanding rheumatoid arthritis. J Clin Med 2021;10:3458.
    OpenUrl
  13. 13.↵
    1. World Health Organization
    . Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
    OpenUrlPubMed
  14. 14.
    1. Mosteller RD.
    Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Inker LA,
    2. Schmid CH,
    3. Tighiouart H, et al.
    Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group
    . KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-50.
    OpenUrlCrossRef
  17. 17.↵
    1. Yokuş O,
    2. Gedik H.
    Etiological causes of pancytopenia: a report of 137 cases. Avicenna J Med 2016;6:109-12.
    OpenUrl
  18. 18.
    1. Sparks JA,
    2. Dellaripa PF,
    3. Glynn RJ, et al.
    Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial. Arthritis Rheumatol 2020;72:2065-71.
    OpenUrl
  19. 19.
    1. Regev A,
    2. Björnsson ES.
    Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology 2014;147:20-4.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Silva-Fernández L,
    2. De Cock D,
    3. Lunt M, et al.
    Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Rheumatology 2018;57:1533-40.
    OpenUrl
  21. 21.↵
    1. Nakashima A,
    2. Horita S,
    3. Matsunaga T, et al.
    Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis. Sci Rep 2021;11:9884.
    OpenUrl
  22. 22.↵
    1. Aronoff GR,
    2. Berns JS,
    3. Brier ME, et al.
    Drug prescribing in renal failure. 5th ed. Philadelphia: American College of Physicians; 2007.
  23. 23.↵
    1. Salliot C,
    2. van der Heijde D.
    Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Ridker PM,
    2. Everett BM,
    3. Pradhan A, et al.
    Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-62.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Mori S,
    2. Hidaka M,
    3. Kawakita T, et al.
    Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PLOS ONE 2016;11:e0154744.
    OpenUrl
  26. 26.
    1. Lee JS,
    2. Oh JS,
    3. Kim YG,
    4. Lee CK,
    5. Yoo B,
    6. Hong S.
    Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 2020;40:765-70.
    OpenUrl
  27. 27.↵
    1. Park GT,
    2. Jeon DW,
    3. Roh KH, et al.
    A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency. Korean J Intern Med 1999;14:85-7.
    OpenUrlPubMed
  28. 28.↵
    1. Benoit SW,
    2. Ciccia EA,
    3. Devarajan P.
    Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn 2020;20:1019-26.
    OpenUrl
  29. 29.↵
    1. Targońska-Stepniak B,
    2. Majdan M.
    Cystatin C concentration is correlated with disease activity in rheumatoid arthritis patients. Scand J Rheumatol 2011;40:341-6.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

cystatin C
glomerular filtration rate
METHOTREXATE
RHEUMATOID ARTHRITIS

Keywords